Acurita

N/A

Report date: 2024/11/29 15:20:29
NME

Base Information

Drug NameAcurita
Drug Alias NameSTP-523STP-601STP-801STP-805STP-900 +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsCyclooxygenase-2 inhibitorsVascular endothelial growth factor inhibitors +[4] 
TargetsEpidermal growth factor receptor erbB1Cyclooxygenase-2Vascular endothelial growth factor +[4] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Macular DegenerationSpinal Cord Injuries +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSirnaomics
China Registration ClassN/A

Develop Information

Active CompaniesSirnaomicsGuangdong Zhongsheng Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Macular DegenerationSpinal Cord Injuries +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A